leadf
logo-loader
viewShield Therapeutics PLC

Shield Therapeutics to present data showing Feraccru offers 'real oral alternative'

Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru.

He says the trial shows the drug, also known as Accrufer in the States, offers a real oral alternative to intravenous iron for patients with iron deficiency anaemia.

Quick facts: Shield Therapeutics PLC

Price: 143 GBX

LSE:STX
Market: LSE
Market Cap: £167.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE falters as US Federal Reserve decision takes centre stage

The FTSE 100 mixed this Wednesday after the (OECD) said the global economy is set to shrink 4.5% in 2020, which is not as bad as the 6% collapse it had forecast in June. Also today - the UK’s inflation fell to 0.2% in August, from 1% in July - due largely to the ‘Eat out to help out’ government...

2 days, 10 hours ago

2 min read